Which patients can use giritinib/segatan?

Gilitinib is a new generation of targeted anti-cancer drugs, mainly used to treat adult patients with relapsed or refractory FLT3 mutation-positive acute myeloid leukemia (AML). AML is an aggressive hematological malignancy with a higher relapse rate after traditional chemotherapy, and patients with FLT3 mutations have a worse prognosis. Such mutations drive the abnormal proliferation of leukemia cells. As an oral small molecule tyrosine kinase inhibitor, giritinib can effectively target FLT3-ITD and FLT3-TKD mutations and block related signaling pathways, thereby inhibiting the growth of leukemia cells and delaying disease progression.

In clinical application, the main people suitable for the use of giritinib are AML patients who still relapse after standard chemotherapy or hematopoietic stem cell transplantation, or who have insufficient response to previous treatment. Unlike traditional chemotherapy, giritinib does not rely on cytotoxicity mechanisms, but achieves treatment by precisely inhibiting gene mutation pathways. Therefore, it also provides new treatment hope for patients with weak constitutions who cannot tolerate intensive chemotherapy. In addition, giritinib has shown a higher response rate and longer survival benefit as a monotherapy, and is particularly valuable for patients who wish to seek alternative or bridging therapy with oral targeted drugs.

It is worth noting that not all geritinibAML patients can be used. Only when genetic testing confirms the presence of FLT3 mutation, the drug will show significant efficacy, so in clinical practice, molecular testing is usually required to screen suitable people. This gene-driven precision medicine model also reflects the development trend of modern tumor treatment. With the popularization of testing methods and the improvement of drug accessibility, giritinib will become an important part of personalized treatment of AML, extending survival and improving quality of life for more patients.

Reference materials:https://www.xospata.com/